Report Library
View More
Datamonitor Healthcare Oncology Dis...
March 23, 2023
Datamonitor Healthcare Oncology: NH...
March 23, 2023
Datamonitor Healthcare CV&Met: Amyl...
March 23, 2023
Prostate Cancer KOL Interview - Ita...
March 22, 2023
Datamonitor Healthcare I&I: Dry Eye...
March 21, 2023
Datamonitor Healthcare CV&Met Disea...
March 21, 2023
Datamonitor Healthcare Oncology: Ne...
March 21, 2023
Datamonitor Healthcare Other: Benig...
March 21, 2023
Datamonitor Healthcare Oncology Dis...
March 20, 2023
Datamonitor Healthcare Oncology Dis...
March 17, 2023
Impact Events
More| Date | Lead Company | Event | Type | Approval Change | Approval Likelihood |
|---|---|---|---|---|---|
| 3/21/23 | Altimmune (ALT) | Pemvidutide for Obesity | Subscribers Only | Subscribers Only | Subscribers Only |
| 3/21/23 | Altimmune (ALT) | Pemvidutide for Diabetes Mellitus, Type II | Subscribers Only | Subscribers Only | Subscribers Only |
| 3/20/23 | Biogen (BIIB) | Tofersen for Amyotrophic Lateral Sclerosis (ALS) | Subscribers Only | Subscribers Only | Subscribers Only |
| 3/16/23 | Astellas Pharma (4503:JP) | Xtandi for Prostate Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
| 3/16/23 | Pfizer (PFE) | Paxlovid for COVID-19 Treatment | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
More| Expected Date Range | Lead Company | Drug | Expected Catalyst |
|---|---|---|---|
| 03/22/23 | Subscribers Only | Subscribers Only | Trial Data - Top-Line Results |
| 03/22/23 | Subscribers Only | Subscribers Only | Trial Announcement - Trial Completion |
| 03/22/23 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |
| 03/22/23 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 03/22/23 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |
